Veristat, LLC

04/22/2026

We have exciting news to share.

Veristat has announced its intended acquisition of Certara’s Regulatory and Medical Writing business, a division of Certara known for its white-glove advisory services and expertise authoring clinical and non-clinical documents throughout the drug development lifecycle.

Certara's Regulatory and Medical Writing business brings a full range of capabilities that complement and deepen what Veristat already delivers:

- Clinical documentation and regulatory medical writing

- Safety writing, including periodic safety update reports and cumulative safety analysis

- Submission leadership: strategy, planning, and delivery for biopharma sponsors

- CMC services, including chemistry, manufacturing and controls analysis

- Regulatory operations: eCTD submissions and global health authority filings

- Medical publishing and document quality

Together, Veristat and Certara's Regulatory and Medical Writing business will have unmatched capabilities in biostatistics, medical writing, and regulatory affairs, united by a shared focus on science-based insights, strong client partnerships, innovation, and impact.

🔗 https://lnkd.in/gAdkguAY

02/28/2026

On Rare Disease Day, we recognize the millions of individuals and families living with conditions that often go undiagnosed, misunderstood, or overlooked.

Rare diseases may affect smaller populations, but the impact on daily life is significant. Today is a reminder of the importance of awareness, early diagnosis, scientific advancement, and community support.

Together, we can help bring visibility to the challenges and resilience within rare disease communities 🤝

02/26/2026

Bringing a therapy from early development to approval requires coordination across clinical, regulatory, and operational functions.

In this video, our team shares how Veristat supports sponsors through each stage, helping them navigate complexity and keep development moving forward.

📽️ Watch the video to learn more about our integrated approach 👇

02/25/2026

In rare disease trials, the challenge isn’t just analyzing data, it’s understanding what the data is truly saying. Study design, endpoint selection, interim analyses, and how uncertainty is handled all shape the decisions that follow. Biostatistics brings discipline and judgment to those moments, helping clients interpret results with confidence and ensuring conclusions are grounded in both science and patient impact.

Learn how Veristat’s biostatistics and statistical programming expertise supports sound decisions across complex and rare disease trials.

02/24/2026

Oncology submissions move fast, and the stakes couldn’t be higher. Sponsors need a partner who can keep pace without compromising scientific rigor.

This infographic highlights why an oncology‑focused CRO makes a difference:
🔷 Proactive planning to meet accelerated timelines
🔷 Seamless collaboration across writing, stats, and publishing
🔷 Expertise in oncology‑specific pathways like RTOR and Project Orbis
🔷 Deep experience with complex datasets and adaptive study designs

When every day counts, experience and precision matter.

👉 Download the infographic in the first comment.

02/23/2026

In rare and ultra-rare disease programs, from protocols and clinical study reports to regulatory submissions and patient-facing materials, how data is communicated can influence regulatory review, development decisions, and ultimately patient access.

Medical writing sits at the intersection of science, regulation, and clarity. It’s where complex data is shaped into a coherent narrative that highlights efficacy and safety, aligns with evolving global requirements, and supports confident regulatory outcomes, without losing sight of the patients behind the science.

Learn how Veristat’s medical writing team bridges science and regulatory success, and why experience, precision, and regulatory fluency matter at every stage of development.

02/20/2026

Institutional knowledge is the backbone of successful M&A. Without it, organizations risk losing efficiency, compliance, and competitive advantage.

In our blog, we share actionable steps to capture and retain expertise during mergers and acquisitions, so your teams stay aligned, and your projects stay on track.

Protecting what matters most ensures long-term value and stability.

👉 Link in the first comment.

02/18/2026

From detection to decision-making: ctDNA is emerging as a powerful tool in oncology.

By providing real-time insights into tumor dynamics, ctDNA can help clinicians tailor treatments more effectively.

Learn how this innovation could optimize patient care.

02/17/2026

In rare disease research, the margin for error is small. Patient populations are limited, timelines matter, and every decision is built on the data collected along the way.

That’s why data management isn’t just about systems and checks, it’s about stewardship. Ensuring the data is complete, consistent, and trustworthy so our clients, regulators, and clinicians can move forward with confidence, and patients aren’t left waiting.

Learn how integrated data management, biostatistics, and statistical programming work together to deliver data that truly matters in our ebook (link below).

02/16/2026

We’re excited to share this new BioXconomy feature spotlighting Kim Boericke, Veristat’s CEO.

The article highlights her immediate priorities for expanding Veristat, emphasizing a focus on people, strategic consulting, and therapeutic specialization, along with her role as one of the minority of women leaders in the life sciences industry.

Read the full story here:
👉 https://hubs.li/Q0437DWx0

Industry veteran Boericke becomes Veristat CEO, bringing 25+ years experience. She plans expansion in oncology, AI integration